Incidence of treatment-resistant depression during the first mood depressive episode

##plugins.themes.academic_pro.article.sidebar##

Published Aug 24, 2023
Download
PDF
Vol. 101 No. 3 (2023): Tunis Med mars 2023

##plugins.themes.academic_pro.article.main##

Maroua Said
Public Mental Health Establishment in Marne (France).
Rania Hosni
Psychiatry Department A, Razi hospital, Tunis, Tunisia
Hend Jemli
Psychiatry Department A, Razi hospital, Tunis, Tunisia
Yosra Zgueb
Psychiatry Department A, Razi hospital, Tunis, Tunisia
Uta Ouali
Psychiatry Department A, Razi hospital, Tunis, Tunisia
Haifa Zalila
Outpatient Psychiatry Department, Razi Hospital, Tunisia
Fethi Nacef
Psychiatry Department A, Razi hospital, Tunis, Tunisia
Rabaa Jomli
Psychiatry Department A, Razi hospital, Tunis, Tunisia

Abstract

ackground: In spite of several approaches and therapeutic measures, treatment-resistant depression (TRD) continues to inflict serious, individual
and collective consequences. Therefore, there is a persistent need to scrutinize the concept of TRD in order to adapt the therapeutic strategies.
Aim : To estimate the incidence of TRD in patients with a first major depressive episode (MDD), and study factors associated with resistance.
Methods: A descriptive prospective longitudinal study of outpatients with a first MDD, was conducted. Patients with a history of subthreshold
hypomania were excluded. Eligible patients were put on a selective serotonin reuptake inhibitor (SSRI), either fluoxetine or sertraline. Participants
were followed regularly until they had a therapeutic response or they met the criteria for TRD.
Results: The study involved 82 adults. The incidence of treatment-resistant depression was 19.4% CI95%=[5.5-33.3]. Among the sociodemographic
and clinical factors, family history of psychosis (p=0.038) and chronic respiratory comorbidities (p=0.016) were associated with TRD. The small size
of the sample is a potential limitation of this study. Besides, the use of only two SSRIs could influence the results.
Conclusion: In this study, the incidence of TRD was at the lower limit of the rates reported in clinical studies. Clinical factors associated with
TRD suggest the relevance of genotype analysis to identify patients with TRD. Furthermore, our results highlight the importance of heeding
comorbidities to optimize care. Larger multicenter studies are sneeded to generalize

Keywords:

resistant depression, incidence, fluoxetin, sertralin

##plugins.themes.academic_pro.article.details##

Creative Commons License

This work is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License.

References

  1. Depression [WWW Document]. WHO, 2019. Accessed December 30, 2019. https://www.who.int/news-room/fact-sheets/detail/depression
  2. Richards D. Prevalence and clinical course of depression: a review. Clin Psychol Rev. 2011;31 (7):1117-1125. doi:10.1016/j.cpr.2011.07.004
  3. Rao D, Xu G, Lu Z, Liang H, Lin K, Tang M. Comparative Study of Cognitive Function Between Treatment-Resistant Depressive Patients and First-Episode Depressive Patients. Neuropsychiatr Dis Treat. 2019;15:3411-3417. doi:10.2147/NDT.S226405
  4. Li G, Fife D, Wang G, et al. All-cause mortality in patients with treatment-resistant depression: a cohort study in the US population. Ann Gen Psychiatry. 2019;18:23. doi:10.1186/s12991-019-0248-0
  5. McCrone P, Rost F, Koeser L, et al. The economic cost of treatment-resistant depression in patients referred to a specialist service. J Ment Health Abingdon Engl. 2018;27 (6):567-573. doi:10.1080/09638237.2017.1417562
  6. Sussman M, O’sullivan AK, Shah A, Olfson M, Menzin J. Economic Burden of Treatment-Resistant Depression on the U.S. Health Care System. J Manag Care Spec Pharm. 2019;25 (7):823-835. doi:10.18553/jmcp.2019.25.7.823
  7. Gibson TB, Jing Y, Smith Carls G, et al. Cost burden of treatment resistance in patients with depression. Am J Manag Care. 2010;16 (5):370-377.
  8. Demyttenaere K, Van Duppen Z. The Impact of (the Concept of) Treatment-Resistant Depression: An Opinion Review. Int J Neuropsychopharmacol. 2019;22 (2):85-92. doi:10.1093/ijnp/pyy052
  9. Souery D, Oswald P, Massat I, et al. Clinical factors associated with treatment resistance in major depressive disorder: results from a European multicenter study. J Clin Psychiatry. 2007;68 (7):1062-1070. doi:10.4088/jcp.v68n0713
  10. Kim SYH, De Vries RG, Peteet JR. Euthanasia and Assisted Suicide of Patients With Psychiatric Disorders in the Netherlands 2011 to 2014. JAMA Psychiatry. 2016;73 (4):362-368. doi:10.1001/jamapsychiatry.2015.2887
  11. Papakostas GI, Fava M. Pharmacotherapy for Depression and Treatment-Resistant Depression. WORLD SCIENTIFIC; 2010. doi:10.1142/7468
  12. Thienpont L, Verhofstadt M, Van Loon T, Distelmans W, Audenaert K, De Deyn PP. Euthanasia requests, procedures and outcomes for 100 Belgian patients suffering from psychiatric disorders: a retrospective, descriptive study. BMJ Open. 2015;5 (7):e007454. doi:10.1136/bmjopen-2014-007454
  13. Scherrer JF, Chrusciel T, Garfield LD, et al. Treatment-resistant and insufficiently treated depression and all-cause mortality following myocardial infarction. Br J Psychiatry J Ment Sci. 2012;200 (2):137-142. doi:10.1192/bjp.bp.111.096479
  14. Ruhé HG, van Rooijen G, Spijker J, Peeters FPML, Schene AH. Staging methods for treatment resistant depression. A systematic review. J Affect Disord. 2012;137 (1-3):35-45. doi:10.1016/j.jad.2011.02.020
  15. Malhi GS, Das P, Mannie Z, Irwin L. Treatment-resistant depression: problematic illness or a problem in our approach? Br J Psychiatry J Ment Sci. 2019;214 (1):1-3. doi:10.1192/bjp.2018.246
  16. Fekadu A, Wooderson S, Donaldson C, et al. A multidimensional tool to quantify treatment resistance in depression: the Maudsley staging method. J Clin Psychiatry. 2009;70 (2):177-184. doi:10.4088/jcp.08m04309
  17. Gaynes BN, Lux L, Gartlehner G, et al. Defining treatment-resistant depression. Depress Anxiety. 2020;37 (2):134-145. doi:10.1002/da.22968
  18. Ng CH, Kato T, Han C, et al. Definition of treatment-resistant depression - Asia Pacific perspectives. J Affect Disord. 2019;245:626-636. doi:10.1016/j.jad.2018.11.038
  19. Fava M, Davidson KG. Definition and epidemiology of treatment-resistant depression. Psychiatr Clin North Am. 1996;19 (2):179-200. doi:10.1016/s0193-953x (05)70283-5
  20. Friedman ES, Anderson I. Handbook of Depression: Second Edition. Springer Healthcare Communications; 2014. doi:10.1007/978-1-907673-79-5
  21. Sinyor M, Schaffer A, Levitt A. The sequenced treatment alternatives to relieve depression (STAR*D) trial: a review. Can J Psychiatry Rev Can Psychiatr. 2010;55 (3):126-135. doi:10.1177/070674371005500303
  22. Rizvi SJ, Grima E, Tan M, et al. Treatment-resistant depression in primary care across Canada. Can J Psychiatry Rev Can Psychiatr. 2014;59 (7):349-357. doi:10.1177/070674371405900702
  23. Sackeim HA, Aaronson ST, Bunker MT, et al. The assessment of resistance to antidepressant treatment: Rationale for the Antidepressant Treatment History Form: Short Form (ATHF-SF). J Psychiatr Res. 2019;113:125-136. doi:10.1016/j.jpsychires.2019.03.021
  24. Taylor D, Paton C, Kapur S. Maudsley Prescribing Guidelines in Psychiatry. John Wiley & Sons; 2015.
  25. Targum SD. Identification and treatment of antidepressant tachyphylaxis. Innov Clin Neurosci. 2014;11 (3-4):24-28.
  26. Wijeratne C, Sachdev P. Treatment-resistant depression: critique of current approaches. Aust N Z J Psychiatry. 2008;42 (9):751-762. doi:10.1080/00048670802277206
  27. Kocsis JH, Gelenberg AJ, Rothbaum B, et al. Chronic forms of major depression are still undertreated in the 21st century: systematic assessment of 801 patients presenting for treatment. J Affect Disord. 2008;110 (1-2):55-61. doi:10.1016/j.jad.2008.01.002
  28. Cepeda MS, Reps J, Fife D, Blacketer C, Stang P, Ryan P. Finding treatment-resistant depression in real-world data: How a data-driven approach compares with expert-based heuristics. Depress Anxiety. 2018;35 (3):220-228. doi:10.1002/da.22705
  29. Sackeim HA, Roose SP, Lavori PW. Determining the duration of antidepressant treatment: application of signal detection methodology and the need for duration adaptive designs (DAD). Biol Psychiatry. 2006;59 (6):483-492. doi:10.1016/j.biopsych.2005.08.033
  30. Kautzky A, Dold M, Bartova L, et al. Clinical factors predicting treatment resistant depression: affirmative results from the European multicenter study. Acta Psychiatr Scand. 2019;139 (1):78-88. doi:10.1111/acps.12959
  31. Gronemann FH, Jorgensen MB, Nordentoft M, Andersen PK, Osler M. Socio-demographic and clinical risk factors of treatment-resistant depression: A Danish population-based cohort study. J Affect Disord. 2020;261:221-229. doi:10.1016/j.jad.2019.10.005
  32. van Belkum SM, Geugies H, Lysen TS, et al. Validity of the Maudsley Staging Method in Predicting Treatment-Resistant Depression Outcome Using the Netherlands Study of Depression and Anxiety. J Clin Psychiatry. 2018;79 (1):17m11475. doi:10.4088/JCP.17m11475
  33. Tabeleão V, Tomasi E, de Avila Quevedo L. A Randomized, Controlled Trial of the Effectiveness of a Psychoeducational Intervention on Family Caregivers of Patients with Mental Disorders. Community Ment Health J. 2018;54 (2):211-217. doi:10.1007/s10597-017-0126-7
  34. van Wijngaarden B, Schene AH, Koeter MWJ. Family caregiving in depression: impact on caregivers’ daily life, distress, and help seeking. J Affect Disord. 2004;81 (3):211-222. doi:10.1016/S0165-0327 (03)00168-X
  35. Francesca MM, Efisia LM, Alessandra GM, Marianna A, Giovanni CM. Misdiagnosed hypomanic symptoms in patients with treatment-resistant major depressive disorder in Italy: results from the improve study. Clin Pract Epidemiol Ment Health CP EMH. 2014;10:42-47. doi:10.2174/1745017901410010042
  36. Meyer TD, Schrader J, Ridley M, Lex C. The Hypomania Checklist (HCL) - systematic review of its properties to screen for bipolar disorders. Compr Psychiatry. 2014;55 (5):1310-1321. doi:10.1016/j.comppsych.2014.03.002
  37. Rybakowski JK, Dudek D, Pawlowski T, Lojko D, Siwek M, Kiejna A. Use of the Hypomania Checklist-32 and the Mood Disorder Questionnaire for detecting bipolarity in 1051 patients with major depressive disorder. Eur Psychiatry J Assoc Eur Psychiatr. 2012;27 (8):577-581. doi:10.1016/j.eurpsy.2010.12.001
  38. Hamilton M. A rating scale for depression. J Neurol Neurosurg Psychiatry. 1960;23:56-62. doi:10.1136/jnnp.23.1.56
  39. Thomas L, Kessler D, Campbell J, et al. Prevalence of treatment-resistant depression in primary care: cross-sectional data. Br J Gen Pract J R Coll Gen Pract. 2013;63 (617):e852-858. doi:10.3399/bjgp13X675430
  40. Chiarotti F, Viglione A, Giuliani A, Branchi I. Citalopram amplifies the influence of living conditions on mood in depressed patients enrolled in the STAR*D study. Transl Psychiatry. 2017;7 (3):e1066. doi:10.1038/tp.2017.35
  41. Nemeroff CB. Prevalence and management of treatment-resistant depression. J Clin Psychiatry. 2007;68 Suppl 8:17-25.
  42. Saveanu R, Etkin A, Duchemin A-M, et al. The international Study to Predict Optimized Treatment in Depression (iSPOT-D): outcomes from the acute phase of antidepressant treatment. J Psychiatr Res. 2015;61:1-12. doi:10.1016/j.jpsychires.2014.12.018
  43. Ruhé HG, Huyser J, Swinkels JA, Schene AH. Switching antidepressants after a first selective serotonin reuptake inhibitor in major depressive disorder: a systematic review. J Clin Psychiatry. 2006;67 (12):1836-1855. doi:10.4088/jcp.v67n1203
  44. Brown WA, Harrison W. Are patients who are intolerant to one SSRI intolerant to another? Psychopharmacol Bull. 1992;28 (3):253-256.
  45. Thase ME, Blomgren SL, Birkett MA, Apter JT, Tepner RG. Fluoxetine treatment of patients with major depressive disorder who failed initial treatment with sertraline. J Clin Psychiatry. 1997;58 (1):16-21. doi:10.4088/jcp.v58n0103
  46. Ferreri M, Lavergne F, Berlin I, Payan C, Puech AJ. Benefits from mianserin augmentation of fluoxetine in patients with major depression non-responders to fluoxetine alone. Acta Psychiatr Scand. 2001;103 (1):66-72. doi:10.1034/j.1600-0447.2001.00148.x
  47. Souery D, Serretti A, Calati R, et al. Switching antidepressant class does not improve response or remission in treatment-resistant depression. J Clin Psychopharmacol. 2011;31 (4):512-516. doi:10.1097/JCP.0b013e3182228619
  48. Warden D, Rush AJ, Trivedi MH, Fava M, Wisniewski SR. The STAR*D Project results: a comprehensive review of findings. Curr Psychiatry Rep. 2007;9 (6):449-459. doi:10.1007/s11920-007-0061-3
  49. Zarate CA, Kando JC, Tohen M, Weiss MK, Cole JO. Does intolerance or lack of response with fluoxetine predict the same will happen with sertraline? J Clin Psychiatry. 1996;57 (2):67-71.
  50. Fife D, Feng Y, Wang MY-H, et al. Epidemiology of pharmaceutically treated depression and treatment resistant depression in Taiwan. Psychiatry Res. 2017;252:277-283. doi:10.1016/j.psychres.2017.03.006
  51. Kubitz N, Mehra M, Potluri RC, Garg N, Cossrow N. Characterization of treatment resistant depression episodes in a cohort of patients from a US commercial claims database. PloS One. 2013;8 (10):e76882. doi:10.1371/journal.pone.0076882
  52. Serretti A, Chiesa A, Calati R, Perna G, Bellodi L, De Ronchi D. Common genetic, clinical, demographic and psychosocial predictors of response to pharmacotherapy in mood and anxiety disorders. Int Clin Psychopharmacol. 2009;24 (1):1-18. doi:10.1097/YIC.0b013e32831db2d7
  53. Young EA, Kornstein SG, Marcus SM, et al. Sex differences in response to citalopram: a STAR*D report. J Psychiatr Res. 2009;43 (5):503-511. doi:10.1016/j.jpsychires.2008.07.002
  54. Kornstein SG, Schatzberg AF, Thase ME, et al. Gender differences in treatment response to sertraline versus imipramine in chronic depression. Am J Psychiatry. 2000;157 (9):1445-1452. doi:10.1176/appi.ajp.157.9.1445
  55. Husain MM, Rush AJ, Wisniewski SR, et al. Family history of depression and therapeutic outcome: findings from STAR*D. J Clin Psychiatry. 2009;70 (2):185-195. doi:10.4088/jcp.07m03571
  56. Serretti A, Calati R, Oasi O, De Ronchi D, Colombo C. Dissecting the determinants of depressive disorders outcome: an in depth analysis of two clinical cases. Ann Gen Psychiatry. 2007;6:5. doi:10.1186/1744-859X-6-5
  57. Rihmer Z, Dome P, Gonda X. Antidepressant response and subthreshold bipolarity in “unipolar” major depressive disorder: implications for practice and drug research. J Clin Psychopharmacol. 2013;33 (4):449-452. doi:10.1097/JCP.0b013e318299d2d5
  58. Carroll LS, Owen MJ. Genetic overlap between autism, schizophrenia and bipolar disorder. Genome Med. 2009;1 (10):102. doi:10.1186/gm102
  59. Sugawara H, Murata Y, Ikegame T, et al. DNA methylation analyses of the candidate genes identified by a methylome-wide association study revealed common epigenetic alterations in schizophrenia and bipolar disorder. Psychiatry Clin Neurosci. 2018;72 (4):245-254. doi:10.1111/pcn.12645
  60. Green EK, Grozeva D, Jones I, et al. The bipolar disorder risk allele at CACNA1C also confers risk of recurrent major depression and of schizophrenia. Mol Psychiatry. 2010;15 (10):1016-1022. doi:10.1038/mp.2009.49
  61. Dudek D, Siwek M, Zielińska D, Jaeschke R, Rybakowski J. Diagnostic conversions from major depressive disorder into bipolar disorder in an outpatient setting: results of a retrospective chart review. J Affect Disord. 2013;144 (1-2):112-115. doi:10.1016/j.jad.2012.06.014
  62. Masson E. Prévalence de l’hypomanie dans les dépressions majeures récurrentes ou résistantes : enquêtes Bipolact. EM-Consulte. Accessed October 14, 2021. https://www.em-consulte.com/article/200588/prevalence-de-lhypomanie-dans-les-depressions-maje
  63. Perlis RH. A clinical risk stratification tool for predicting treatment resistance in major depressive disorder. Biol Psychiatry. 2013;74 (1):7-14. doi:10.1016/j.biopsych.2012.12.007
  64. Hirschfeld RM, Russell JM, Delgado PL, et al. Predictors of response to acute treatment of chronic and double depression with sertraline or imipramine. J Clin Psychiatry. 1998;59 (12):669-675. doi:10.4088/jcp.v59n1205
  65. Trivedi MH, Rush AJ, Wisniewski SR, et al. Evaluation of outcomes with citalopram for depression using measurement-based care in STAR*D: implications for clinical practice. Am J Psychiatry. 2006;163 (1):28-40. doi:10.1176/appi.ajp.163.1.28
  66. Worthington J, Fava M, Agustin C, et al. Consumption of alcohol, nicotine, and caffeine among depressed outpatients. Relationship with response to treatment. Psychosomatics. 1996;37 (6):518-522. doi:10.1016/S0033-3182 (96)71515-3
  67. Kool S, Schoevers R, de Maat S, et al. Efficacy of pharmacotherapy in depressed patients with and without personality disorders: a systematic review and meta-analysis. J Affect Disord. 2005;88 (3):269-278. doi:10.1016/j.jad.2005.05.017
  68. Rush AJ, Wisniewski SR, Warden D, et al. Selecting among second-step antidepressant medication monotherapies: predictive value of clinical, demographic, or first-step treatment features. Arch Gen Psychiatry. 2008;65 (8):870-880. doi:10.1001/archpsyc.65.8.870
  69. Gill D, Hatcher S. Antidepressants for depression in medical illness. Cochrane Database Syst Rev. 2000; (4):CD001312. doi:10.1002/14651858.CD001312
  70. Krishnan KRR. Comorbidity and depression treatment. Biol Psychiatry. 2003;53 (8):701-706. doi:10.1016/s0006-3223 (02)01787-0
  71. Borson S, McDonald GJ, Gayle T, Deffebach M, Lakshminarayan S, VanTuinen C. Improvement in mood, physical symptoms, and function with nortriptyline for depression in patients with chronic obstructive pulmonary disease. Psychosomatics. 1992;33 (2):190-201. doi:10.1016/S0033-3182 (92)71995-1
  72. Eiser N, Harte R, Spiros K, Phillips C, Isaac MT. Effect of treating depression on quality-of-life and exercise tolerance in severe COPD. COPD. 2005;2 (2):233-241.
  73. Kankaanranta H, Kauppi P, Tuomisto LE, Ilmarinen P. Emerging Comorbidities in Adult Asthma: Risks, Clinical Associations, and Mechanisms. Mediators Inflamm. 2016;2016:3690628. doi:10.1155/2016/3690628
  74. Martinez Rivera C, Costan Galicia J, Alcázar Navarrete B, et al. Factors Associated with Depression in COPD: A Multicenter Study. Lung. 2016;194 (3):335-343. doi:10.1007/s00408-016-9862-7
  75. Brown ES, Howard C, Khan DA, Carmody TJ. Escitalopram for severe asthma and major depressive disorder: a randomized, double-blind, placebo-controlled proof-of-concept study. Psychosomatics. 2012;53 (1):75-80. doi:10.1016/j.psym.2011.07.009
  76. Smoller JW, Pollack MH, Systrom D, Kradin RL. Sertraline effects on dyspnea in patients with obstructive airways disease. Psychosomatics. 1998;39 (1):24-29. doi:10.1016/S0033-3182 (98)71377-5
  77. Aguglia E, Casacchia M, Cassano GB, et al. Double-blind study of the efficacy and safety of sertraline versus fluoxetine in major depression. Int Clin Psychopharmacol. 1993;8 (3):197-202. doi:10.1097/00004850-199300830-00010
  78. Bennie EH, Mullin JM, Martindale JJ. A double-blind multicenter trial comparing sertraline and fluoxetine in outpatients with major depression. J Clin Psychiatry. 1995;56 (6):229-237.